Can Chromosomal Abnormalities Go to Hong Kong for IVF? PGT Technical Pathways and Applicable Conditions

AI Summary

Scenario Opening: Real Consultation Module A: Direct Answer to the Question

I. Direct Answer: Is it Feasible to Go to Hong Kong for IVF with Chromosomal Abnormalities?

Yes, it is feasible, but medical indications must be met. Patients with chromosomal abnormalities can undergo IVF in Hong Kong. Hong Kong's reproductive medicine centers have a comprehensive PGT (Preimplantation Genetic Testing) technology system capable of performing genetic screening at the embryonic level for different types of chromosomal abnormalities. However, a prerequisite needs to be clarified: not all types of chromosomal abnormalities are suitable for resolution through PGT, nor can all patients receive the same testing protocol at Hong Kong fertility centers. Whether it can be performed and which testing strategy is adopted depends on comprehensive factors such as the type of chromosomal abnormality, the patient's reproductive history, age, and ovarian reserve function.

From a technical pathway perspective, PGT in Hong Kong is divided into two main types:

• PGT-A (Aneuploidy Screening): Suitable for individuals of advanced maternal age, those with recurrent implantation failure, recurrent miscarriage suspected to be related to embryonic chromosomal numerical abnormalities. PGT-A checks whether the number of chromosomes in the embryo is normal (i.e., whether there is an increase or decrease in the number of 23 pairs of chromosomes), but it cannot detect structural abnormalities.
• PGT-SR (Structural Rearrangement Screening): Specifically designed for carriers of chromosomal structural abnormalities, such as balanced translocations, Robertsonian translocations, pericentric inversions, paracentric inversions, etc. PGT-SR can identify whether an embryo carries an unbalanced structural rearrangement, thereby selecting embryos with normal chromosomal structure for transfer.

For patients with chromosomal abnormalities, the core value of going to Hong Kong for IVF is that PGT testing in Hong Kong is usually performed by laboratories with international accreditations (such as CAP, CLIA), offering relatively higher testing coverage and resolution, and a more standardized genetic counseling system.

Module C: The Doctor's Perspective

II. Doctor's Perspective: Suitability of Chromosomal Abnormalities and PGT Technology

From a clinical reproductive medicine perspective, chromosomal abnormalities are a significant cause of recurrent implantation failure, recurrent miscarriage, and fetal chromosomal abnormalities. For carriers of structural abnormalities (e.g., balanced translocations, Robertsonian translocations, pericentric inversions), PGT-SR is the current mainstream intervention. For increased risk of embryonic aneuploidy due to advanced maternal age, PGT-A is a commonly used screening tool.

Fertility centers in Hong Kong started early in the PGT field, with relatively mature laboratory quality control systems, providing a relatively stable testing environment. However, doctors emphasize that PGT itself is a screening technology, not a diagnostic technology, and has certain limitations and detection blind spots:

• PGT cannot detect all types of chromosomal abnormalities. For example, some microdeletion/microduplication syndromes, imprinting gene abnormalities, etc., may not be detectable by standard PGT platforms.
• PGT-SR has limited detection capability for complex rearrangements (involving three or more chromosomes), and in some cases, clear test results may not be obtainable.
• Embryo biopsy itself has a potential impact on the embryo. Although blastocyst biopsy is currently considered relatively safe, it is not zero-risk.

Therefore, when evaluating whether a patient with chromosomal abnormalities is suitable for IVF in Hong Kong, doctors focus on the following three conditions:

1. Type and specific karyotype of the chromosomal abnormality: Whether it falls within the detectable range of PGT technology.
2. Ovarian reserve function: The PGT process requires a certain number of blastocysts for biopsy; insufficient ovarian reserve may result in no embryos available for testing.
3. Previous reproductive history: Whether there is a history of recurrent miscarriage, embryonic arrest, or pregnancy with a chromosomally abnormal fetus.

Module I: Actual Process

III. Specific Process for PGT IVF in Hong Kong

For patients with chromosomal abnormalities undergoing IVF in Hong Kong, the process is roughly divided into five stages:

Stage 1: Preliminary Assessment and Genetic Counseling

• Submit the couple's chromosome karyotype analysis reports (reports from reputable tertiary hospitals in Mainland China are usually accepted, but must be within the validity period).
• Undergo genetic counseling, where a reproductive geneticist assesses the type of chromosomal abnormality, genetic risk, and the suitability of PGT.
• Complete basic fertility assessment: Female AMH, FSH, LH, Antral Follicle Count (AFC); Male semen analysis.
• Routine tests including infectious disease screening, blood type, coagulation function, etc.

Stage 2: Conventional IVF Cycle

• Develop an ovarian stimulation protocol based on the female's ovarian reserve, typically lasting 10-14 days.
• Egg retrieval surgery (performed under intravenous anesthesia, about 15-20 minutes).
• After in vitro fertilization (IVF or ICSI), embryos are cultured in the laboratory to the blastocyst stage (day 5-6).

Stage 3: Blastocyst Biopsy and Genetic Testing

• Biopsy blastocysts that meet testing criteria, taking 3-5 trophectoderm cells.
• Biopsy samples are sent to a genetics laboratory for PGT testing. PGT-A typically uses NGS (Next-Generation Sequencing) or aCGH (array Comparative Genomic Hybridization) platforms; PGT-SR is also based on NGS or SNP array platforms.
• The testing period usually takes 2-4 weeks, depending on the laboratory's workflow and sample volume.

Stage 4: Frozen-Thawed Embryo Transfer

• After test results are available, select chromosomally normal or transferable embryos for frozen-thawed transfer.
• The transfer cycle requires preparing the endometrium using an artificial or natural cycle, typically taking 12-18 days.
• A blood hCG test is performed 12-14 days after transfer to confirm pregnancy.

Stage 5: Post-Pregnancy Prenatal Diagnosis Confirmation

• After PGT pregnancy, it is recommended to undergo amniocentesis at 16-20 weeks of gestation for prenatal diagnosis confirmation of the fetal chromosome karyotype.
• This is because PGT is a screening technology with the possibility of false positives and false negatives; prenatal diagnosis is the gold standard for final confirmation.

Module J: Time Arrangement

IV. Time Arrangement: How Long from Initial Consultation to Transfer

For patients with chromosomal abnormalities completing a full PGT IVF cycle in Hong Kong, from initial consultation to transfer typically takes 3-4 months. The specific timeline is as follows:

Stage	Time Required	Description
Preliminary Assessment & Genetic Counseling	1-2 weeks	Includes document review, supplementary tests, genetic counseling consultation
Ovarian Stimulation & Egg Retrieval	2-3 weeks	Stimulation starts from day 2 of menstruation, rest 1-2 days after retrieval
Embryo Culture & Biopsy	1-2 weeks	Blastocyst culture to day 5-6, biopsy and send for testing
PGT Testing Period	2-4 weeks	Laboratory testing time, depends on platform and sample volume
Frozen-Thawed Transfer Cycle	2-3 weeks	Endometrial preparation followed by transfer, pregnancy test 12-14 days post-transfer

⏳ If the patient needs to first regulate their health or address other comorbidities (e.g., uterine issues, endocrine disorders), the time will be extended accordingly. Additionally, the PGT testing period may fluctuate depending on the number of embryos.

Module E: Differences Between Countries (Hong Kong vs. Mainland China)

V. Differences in PGT Technology Between Hong Kong and Mainland China

The differences in PGT technology between Hong Kong and Mainland China are mainly reflected in the following dimensions:

Comparison Dimension	Hong Kong	Mainland China
PGT Regulatory Environment	Allows genetic screening of embryos, with relatively broad indications	PGT has strict medical indication restrictions, must comply with National Health Commission regulations
Laboratory Accreditation	Some centers have international accreditations like CAP, CLIA; quality control standards are international	Primarily accredited by the National Health Commission; some top centers also have international accreditations
Detectable Abnormality Types	Wide coverage, including balanced translocations, Robertsonian translocations, inversions, microdeletions, etc.	Mainly focuses on common chromosomal abnormalities; detection of some complex rearrangements is limited
Standardization of Genetic Counseling	Mature genetic counselor system, standardized counseling process	Uneven distribution of genetic counseling resources; some centers have clinical doctors兼任
Cost Level	Higher PGT testing costs; overall cycle cost approximately HKD 150,000-250,000	Relatively lower PGT testing costs; overall cycle cost approximately RMB 80,000-150,000

It is important to note that PGT technology in Hong Kong is not superior to Mainland China in all dimensions. Some large reproductive centers in Mainland China also have excellent technical levels and clinical experience in the PGT field. The choice between Hong Kong and Mainland China should be based on a comprehensive assessment of the patient's specific situation, financial capacity, and requirements for testing scope.

Module G: Most Easily Overlooked Details

VI. Most Easily Overlooked Details

When patients with chromosomal abnormalities undergo IVF in Hong Kong, the following details are often overlooked but are actually very critical:

• Validity of the Chromosome Karyotype Analysis Report: Some Hong Kong fertility centers require chromosome reports issued within the last 6-12 months. If the report is too old, a repeat blood test may be needed.
• Completeness of Genetic Counseling Records: Hong Kong's genetic counseling system requires detailed family history and genetic risk assessment records. If the patient cannot provide complete family genetic information, it may affect the determination of PGT indications.
• Limitations of PGT Testing: PGT-SR cannot distinguish between balanced translocation carriers and completely normal embryos. Some laboratories may report results as "likely normal," requiring patients to fully understand this uncertainty.
• Prenatal Diagnosis Still Required After Transfer: After PGT pregnancy, patients still need to return to Mainland China or undergo amniocentesis prenatal diagnosis in Hong Kong. This is a necessary step to ensure the fetus has normal chromosomes.
• Validity of Mainland China Travel Permits and Endorsements: The length of stay in Hong Kong usually depends on the cycle schedule. It is advisable to confirm the type and validity of the permit/endorsement in advance to avoid treatment delays due to document issues.

Module N: Special Situation Management

VII. Special Situation Management

For patients with chromosomal abnormalities in the following special situations, individualized consideration of the management plan is required:

7.1 Chromosomal Mosaicism

Mosaicism refers to the presence of two or more different cell lines with different karyotypes in the same individual. For mosaic patients, PGT test results may not accurately reflect the true chromosomal status of the embryo. It is recommended to first assess the mosaic ratio and clinical significance through genetic counseling before deciding on the suitability of PGT.

7.2 Complex Chromosomal Rearrangements (Three or More Chromosomes)

Carriers of complex rearrangements may face two issues with PGT-SR testing: first, testing technology may struggle to accurately distinguish between balanced and unbalanced gametes; second, the proportion of embryos available for transfer is extremely low. Such patients need to be mentally prepared in advance and consult experienced reproductive genetics specialists.

7.3 Male Azoospermia Combined with Chromosomal Abnormalities

If the male partner has azoospermia combined with a chromosomal abnormality (e.g., Y chromosome microdeletion, Klinefelter syndrome), sperm must be obtained via testicular/epididymal aspiration, and PGT testing is performed simultaneously. The success rate in such cases is influenced by both sperm quality and embryonic developmental potential.

7.4 Recurrent Miscarriage Combined with Chromosomal Abnormalities

For patients with a history of recurrent miscarriage who are carriers of chromosomal abnormalities, PGT-SR can significantly reduce the miscarriage rate caused by chromosomal imbalance. However, it is important to note that recurrent miscarriage may also be related to uterine issues, immune factors, or endocrine factors, which should be thoroughly investigated before PGT.

Module R: Practitioner Observations

VIII. Practitioner Observations and Objective Advice

As a reproductive physician, clinical observations reveal that patients with chromosomal abnormalities often have certain cognitive biases when choosing to go to Hong Kong for IVF. Here are a few observations from practitioners:

• Overly High Expectations of PGT: Some patients believe that undergoing PGT guarantees a healthy baby. However, PGT cannot change the patient's own chromosomal status, nor can it guarantee 100% normal embryos. In reality, 30%-50% of blastocysts may be deemed non-transferable (due to chromosomal abnormalities), and some patients may have no embryos available for transfer at all.
• Neglecting Assessment of Own Fertility Potential: The success rate of PGT is highly dependent on the number of viable blastocysts. If the female's ovarian reserve is poor (e.g., AMH below 0.5 ng/mL), it may not be possible to obtain enough blastocysts for biopsy, significantly diminishing the value of PGT.
• Misunderstanding of Technology Differences Between Hong Kong and Mainland China: PGT technology in Hong Kong has advantages in some aspects, but the PGT level in top reproductive centers in Mainland China is not inferior. The reason for choosing Hong Kong should be based on preferences regarding testing scope, genetic counseling system, or personal medical experience, rather than simply thinking "Hong Kong's technology is better."

Therefore, it is recommended that patients with chromosomal abnormalities first complete standardized genetic counseling and fertility assessment in Mainland China before making a decision. Clarify whether their type of chromosomal abnormality is suitable for PGT, whether their ovarian reserve is sufficient, and whether there are other comorbidities that need to be addressed. Based on this, compare the PGT protocols and costs of different reproductive centers in Hong Kong and Mainland China to make a rational choice.

Ending: Doctor's Advice (Randomized)

Doctor's Advice

The above content is based on general knowledge of clinical reproductive medicine and does not constitute a recommendation for any specific medical institution or treatment plan. Patients should make decisions based on their own circumstances under the guidance of a professional reproductive physician.

---

— Assisted Reproduction Knowledge Base · Chromosomal Abnormalities Topic —